Compare, Analyse Cipla with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TEVA PHARMA (Israel) - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   TEVA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
TEVA PHARMA
Dec-13
CIPLA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs5863,131-   
Low Rs3572,720-   
Sales per share (Unadj.) Rs207.01,796.9-  
Earnings per share (Unadj.) Rs18.6112.2-  
Cash flow per share (Unadj.) Rs33.2257.5-  
Dividends per share (Unadj.) Rs4.0098.26-  
Dividend yield (eoy) %0.83.4 25.3%  
Book value per share (Unadj.) Rs195.51,996.0-  
Shares outstanding (eoy) m806.35848.00-   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.31.6 139.8%   
Avg P/E ratio x25.326.1 97.2%  
P/CF ratio (eoy) x14.211.4 125.0%  
Price / Book Value ratio x2.41.5 164.4%  
Dividend payout %21.587.5 24.6%   
Avg Mkt Cap Rs m379,9122,480,731 15.3%   
No. of employees `00025.844.9 57.5%   
Total wages/salary Rs m30,2700-   
Avg. sales/employee Rs Th6,459.633,902.6 19.1%   
Avg. wages/employee Rs Th1,171.20-   
Avg. net profit/employee Rs Th580.22,117.9 27.4%   
INCOME DATA
Net Sales Rs m166,9491,523,753 11.0%  
Other income Rs m3,4420-   
Total revenues Rs m170,3911,523,753 11.2%   
Gross profit Rs m32,060417,281 7.7%  
Depreciation Rs m11,747123,166 9.5%   
Interest Rs m1,97429,929 6.6%   
Profit before tax Rs m21,782264,185 8.2%   
Minority Interest Rs m-4751,200 -39.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-173,423 0.0%   
Tax Rs m6,312-3,225 -195.7%   
Profit after tax Rs m14,99595,188 15.8%  
Gross profit margin %19.227.4 70.1%  
Effective tax rate %29.0-1.2 -2,373.5%   
Net profit margin %9.06.2 143.8%  
BALANCE SHEET DATA
Current assets Rs m117,0381,029,137 11.4%   
Current liabilities Rs m43,931897,495 4.9%   
Net working cap to sales %43.88.6 506.9%  
Current ratio x2.71.1 232.3%  
Inventory Days Days9691 105.4%  
Debtors Days Days8596 88.7%  
Net fixed assets Rs m107,424497,691 21.6%   
Share capital Rs m1,6133,751 43.0%   
"Free" reserves Rs m156,0180-   
Net worth Rs m157,6301,692,601 9.3%   
Long term debt Rs m23,693779,129 3.0%   
Total assets Rs m236,6263,482,264 6.8%  
Interest coverage x12.09.8 122.5%   
Debt to equity ratio x0.20.5 32.7%  
Sales to assets ratio x0.70.4 161.2%   
Return on assets %7.23.6 199.6%  
Return on equity %9.55.6 169.2%  
Return on capital %12.84.9 260.4%  
Exports to sales %33.00-   
Imports to sales %00-   
Net fx Rs m49,2720-   
CASH FLOW
From Operations Rs m30,685242,807 12.6%  
From Investments Rs m1,040-86,036 -1.2%  
From Financial Activity Rs m-29,488-291,264 10.1%  
Net Cashflow Rs m2,340-134,493 -1.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 75.01 Rs / USD

Compare CIPLA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare CIPLA With: AJANTA PHARMA  SUN PHARMA  NOVARTIS  UNICHEM LAB  ALEMBIC PHARMA  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views On News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This... (Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun (Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel Views On News (Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

CIPLA SHARE PRICE


Apr 13, 2021 (Close)

TRACK CIPLA

MORE ON CIPLA

CIPLA - GLENMARK PHARMA COMPARISON

COMPARE CIPLA WITH

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS